Human TFRC Stable Cell Line - HeLa

The TFRC gene, located on chromosome 3q29, encodes the transferrin receptor protein 1 (TfR1, also known as CD71), a transmembrane glycoprotein that forms a homodimer on the cell surface and serves as the primary gatekeeper for cellular iron uptake. TfR1 binds to iron-loaded transferrin circulating in the blood and internalizes the complex through receptor-mediated endocytosis, a process that delivers iron into the cell for essential functions including DNA synthesis, respiration, and heme production. Expression of TFRC is tightly regulated at the post-transcriptional level by iron-responsive element-binding proteins that stabilize its mRNA when intracellular iron levels are low. The Human TFRC Stable Cell Line - HeLa is generated by introducing a constitutively active TFRC expression construct into the well-characterized HeLa cervical carcinoma cell line, followed by antibiotic selection to establish a population that consistently overexpresses the transferrin receptor at high levels. This engineered line maintains stable TFRC expression over multiple passages, making it a reliable and reproducible tool for downstream studies.

This stable cell line serves as a valuable platform for investigating iron metabolism, transferrin receptor trafficking, and endocytic pathways in a controlled background. Researchers can use it to study the effects of TFRC overexpression on cellular iron homeostasis, oxidative stress responses, and cell proliferation. Given that TfR1 is highly expressed on many cancer cell types and is a recognized target for drug delivery, the line is particularly useful for evaluating transferrin-conjugated therapeutics, antibody-drug conjugates, and nanoparticle-based delivery systems designed to exploit receptor-mediated uptake. It also enables functional studies of TFRC interacting partners such as HFE, as well as screening for small molecule inhibitors that disrupt transferrin binding or receptor internalization. In addition, the cell line can be employed in mechanistic work exploring how altered iron acquisition influences signaling pathways like HIF-1α and mTOR, or how it modulates sensitivity to ferroptosis and other iron-dependent forms of cell death. With its stable genetic background and consistent TFRC expression, this cell line provides a robust system for both basic research and preclinical therapeutic development.